Merck Serono spin-off, Poxel, has entered into a strategic partnership with Sumitomo Dainippon Pharma for the development and commercialisation of imeglimin, a Phase III-ready therapy in development for the treatment of type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. Imeglimin’s unique mechanism of action means it has the potential to be used at all stages of the diabetes treatment paradigm.